OmniAb (OABI)
NASDAQ:OABI
Want to see OABI full AI Analyst Report?
OABI Stock Chart & Stats
$1.64
-$0.06(-1.65%)
At close: 4:00 PM EST
$1.64
-$0.06(-1.65%)
Day’s Range― - ―
52-Week Range$1.30 - $2.79
Previous CloseN/A
Volume80.31K
Average Volume (3M)561.73K
Market Cap
$339.24M
Enterprise Value$232.38M
Total Cash (Recent Filing)$49.07M
Total Debt (Recent Filing)$19.67M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 06, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding144,972,580
10 Day Avg. Volume481,153
30 Day Avg. Volume561,725
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)0.79
Price to Sales (P/S)11.26
P/FCF Ratio-5.68
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue8.04
Enterprise Value/Gross Profit22.67
Enterprise Value/Ebitda-6.87
Forecast
1Y Price Target
$7.00Price Target Upside326.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$30.46M
Bulls Say, Bears Say
Bulls Say
Large Contracted Milestone And Royalty BaseA sizable, contractually backed $3B+ milestone pool and near-universal contracted economics give durable upside as partner programs advance. These legally enforceable future payments and average royalties create a multi-year pipeline of potential cash inflows that underpin long-term value beyond single-quarter variability.
Recent Revenue Inflection And Raised GuidanceA pronounced YoY revenue rebound and upward guidance reflect stronger monetization of partnerships and milestone realization. This structural inflection increases near-term visibility for recurring deal activity and supports investment in platform commercialization and scaling of discovery services over the next several quarters.
Low Financial Leverage And Near-term Cash BufferVery low debt reduces solvency risk and preserves flexibility to support R&D and partner services. A $49.1M cash balance provides runway to execute operations and pursue commercial traction in the near term, allowing the company to invest in its platforms while seeking milestone or royalty conversion events.
Bears Say
Negative Operating Cash Flow And Declining FCFSustained negative operating cash flow and a near-30% decline in FCF indicate structural cash burn. This trend forces reliance on external financing or milestone timing to fund operations, increasing dilution and constraining strategic flexibility to invest in platform enhancements or scale commercial teams over the medium term.
Deep Operating Losses And Weak MarginsVery large operating losses and a net margin near -188% show the business lacks operating leverage to cover fixed costs. Until revenue mix shifts toward recurring royalties or higher-margin services, sustained losses will erode equity returns and may necessitate cost cuts or fundraising, affecting long-term program support.
Milestone-driven, Lumpy Revenue ModelHeavy reliance on milestone payments creates pronounced quarter-to-quarter volatility and planning difficulty. Because royalties are limited until commercialization, the company lacks stable recurring revenue, making cash flow and operational forecasting sensitive to partner timelines and increasing funding risk over the next 2–6 months.
OmniAb News
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $1.30 and its highest was $2.79 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $339.24M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Aug 06, 2026 which is in 44 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on May 07, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.104 by $0.044.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.12.
How many shares outstanding does OmniAb have?
OmniAb has 144,972,580 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.104. Following the earnings report the stock price went up 12.925%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OmniAb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (326.83% Upside)
$7.00 (326.83% Upside)
Hedge Fund Trend
Decreased
By 285.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.21%
12-Months-Change
Fundamentals
Return on Equity
-20.31%
Trailing 12-Months
Asset Growth
-4.09%
Trailing 12-Months
Company Description
OmniAb
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
OABI Company Deck
OABI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive operational and commercial momentum: a large YoY revenue surge driven by partner milestones, multiple clinical advancements (including OmnidAb entrants and a Phase III progression), improved operating efficiencies, raised revenue guidance, healthy technology traction (xPloration and OmniUltra) and a solid near-term cash balance. Offsetting items include a $2.9M noncash impairment that increased GAAP expense guidance, continued reliance on lumpy milestone revenue rather than royalties, ongoing net losses, and projected year-end cash decline. Overall, the positive operational and revenue developments and guidance raise materially outweigh the lowlights, though risks from milestone variability and funding remain.View all OABI earnings summariesOABI Stock 12 Month Forecast
Average Price Target
$7.00
▲(326.83% Upside)
Technical Analysis
Cartesian Therapeutics
―
Tiziana Life Sciences
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Sagimet Biosciences, Inc. Class A
―
Ownership Overview
5.86% Insiders
10.04% Mutual Funds
18.66% Other Institutional Investors
57.25% Public Companies and
Individual Investors